YahooAugust 21, 2026 at 11:31 AM NY14 days ago
Is Bio-Rad a Buy as Digital PCR Growth Meets a Premium Valuation?
BIO's digital PCR gains and recurring diagnostics base support growth, but a 40.2X forward P/E and muted 2026 outlook keep valuation risk in focus.
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site — Yahoo
Companies in This Story
Related Stories
Exploring the top movers within the S&P500 index during today's session.
ChartMill43 minutes ago
Sector Update: Financial
Yahoo2 hours ago
Will Fiserv’s (FISV) Cut 2026 Outlook and Margin Pressures Change Its Transformation Narrative?
Yahoo2 hours ago
The trading volume of these stocks is deviating from the norm in today's session.
ChartMill2 hours ago
Discover which S&P500 stocks are making waves on Friday.
ChartMill3 hours ago